RedHill Biopharma Explores Opaganib's Role Against Ebola Virus Outbreak

In response to the alarming Ebola virus disease (EVD) outbreak caused by the rare Bundibugyo ebolavirus subtype, RedHill Biopharma has announced its ongoing discussions to advance its investigational drug, opaganib, as a treatment option. Currently, there are no approved medications or vaccines specifically targeting this subtype, which emphasizes the urgent need for effective therapeutic solutions.

The Potential of Opaganib

Opaganib stands out due to its dual action mechanism that targets host cells while directly affecting the virus itself. It works primarily as a selective inhibitor of sphingosine kinase-2 (SPHK2), disrupting essential processes needed for the viral entry and replication. Preclinical studies demonstrated that opaganib inhibited EVD in human macrophages and significantly improved survival rates in animal models. Moreover, its synergistic effects observed when combined with other antiviral agents, such as remdesivir, indicate the potential for enhanced treatment efficacy.

During the development of opaganib, recent phase 3 clinical trials involving patients with severe COVID-19 showcased a remarkable mortality reduction of 70.2% when the drug was used as an add-on to optimal care protocols, which included remdesivir and corticosteroids. Participants treated with opaganib showed a median time to viral RNA clearance that was four days faster than those who received placebo, underscoring its potential utility in pressing health emergencies.

Collaboration with WHO

Recognizing the strain the current Ebola outbreak is placing on global health systems, RedHill is seeking collaborations, notably through the WHO's SOLIDARITY CORE clinical trial platform. This partnership could facilitate rapid clinical evaluation and regulatory discussions concerning opaganib. The company has proactively provided safety, efficacy data, and available supply readiness to relevant health authorities.

Gilead Raday, Chief Operating Officer of RedHill, highlighted the necessity for new therapies in light of recent comments from the World Health Organization which suggest the outbreak is outpacing current response efforts. The multi-faceted action of opaganib may enhance preparedness against infectious disease threats by providing a host-directed therapeutic option that could be used alongside existing antiviral treatments.

An Innovative Approach

What distinguishes opaganib in the field of antiviral therapies is its ability to inhibit multiple pathways through the simultaneous action upon three sphingolipid-metabolizing enzymes in human cells. This capability renders it effective against a range of viruses, including emerging variants, thereby making it a potentially robust tool in the fight against future outbreaks.

Moreover, the oral administration method of opaganib simplifies the logistics of drug distribution and storage, particularly in regions where healthcare infrastructure challenges complicate the response to outbreaks.